The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Open accessAbstract
BACKGROUND: Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis. METHODS: In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 monoclonal antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 monoclonal antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 monoclonal antibody at week 20. RESULTS: There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 monoclonal antibody, in 59% of those who received 90 mg, in 67% of those who received four weekly 45-mg doses, and in 81% of those who received four weekly 90-mg doses, as compared with 2% of those who received placebo (P<0.001 for each comparison), and there was at least 90% improvement in 23%, 30%, 44%, and 52%, respectively, of patients who received the monoclonal antibody as compared with 2% of patients who received placebo (P<0.001 for each comparison). Adverse events occurred in 79% of patients treated with the interleukin-12/23 monoclonal antibody as compared with 72% of patients in the placebo group (P=0.19). Serious adverse events occurred in 4% of patients who received the monoclonal antibody and in 1% of those who received placebo (P=0.69). CONCLUSIONS: This study demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiology of psoriasis. Larger studies are needed to determine whether serious adverse events might limit the clinical usefulness of this new therapeutic target. (ClinicalTrials.gov number, NCT00320216 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Nonparametric Statistics
Groggel, D. J. (2000) · Technometrics · doi:10.1080/00401706.2000.10486067 · Cited by 11,041
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,849
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients
Jong, R. D., Altare, F., Haagen, I.-A., Elferink, D. G., Boer, T. D., van Breda Vriesman, P. J. C., Kabel, P. J., Draaisma, J. M. T., van Dissel, J. T., Kroon, F. P., et al. (1998) · Science · doi:10.1126/science.280.5368.1435 · Cited by 821
Modified Sequentially Rejective Multiple Test Procedures
Shaffer, J. P. (1986) · Journal of the American Statistical Association · doi:10.1080/01621459.1986.10478341 · Cited by 806
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Gottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Self-citationA Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570
Self-citationPiskin, G., Sylva-Steenland, R. M. R., Bos, J. D., & Teunissen, M. B. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1908 · Cited by 454
Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., & Griffiths, C. E. M. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.6.719 · Cited by 363
Self-citationKauffman, C. L., Aria, N., Toichi, E., McCormick, T. S., Cooper, K. D., Gottlieb, A. B., Everitt, D. E., Frederick, B., Zhu, Y., Graham, M. A., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23448.x · Cited by 279
Carlin, C. S., Feldman, S. R., Krueger, J. G., Menter, A., & Krueger, G. G. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.014 · Cited by 278
Self-citationKim, Y.-K., Suh, I.-B., Kim, H., Han, C.-S., Lim, C.-S., Choi, S.-H., & Licinio, J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001084 · Cited by 224
Expression of Interleukin-12 is Increased in Psoriatic Skin
Yawalkar, N., Karlen, S., Hunger, R., Brand, C. U., & Braathen, L. R. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00446.x · Cited by 221
Bruch-Gerharz, D., Fehsel, K., Suschek, C., Michel, G., Ruzicka, T., & Kolb-Bachofen, V (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.2007 · Cited by 184
Murine psoriasis-like disorder induced by naive CD4+ T cells
SchÖn, M. P., Detmar, M., & Parker, C. M. (1997) · Nature Medicine · doi:10.1038/nm0297-183 · Cited by 167
Mini‐review The role of interleukin‐12 in human infectious diseases: only a faint signature
Fieschi, C., & Casanova, J. (2003) · European Journal of Immunology · doi:10.1002/eji.200324038 · Cited by 167
Hong, K., Chu, A. D., Ludviksson, B. R., Berg, E. L., & Ehrhardt, R. O. (1999) · PubMed · Cited by 119
Hong, K., Chu, A. D., Ludviksson, B. R., Berg, E. L., & Ehrhardt, R. O. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7480 · Cited by 111
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant
Overwijk, W. W., de Visser, K. E., Tirion, F. H., de Jong, L. A., Pols, T. W. H., van der Velden, Y. U., van den Boorn, J. G., Keller, A. M., Buurman, W. A., Theoret, M. R., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5213 · Cited by 84
The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation
Barrie, A. M., & Plevy, S. E. (2005) · Clinical and Applied Immunology Reviews · doi:10.1016/j.cair.2005.06.003 · Cited by 27
Cited by
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Metadata
- Authors
- Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., & Lebwohl, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-02-08
- Volume
- 356
- Issue
- 6
- Pages
- 580-592
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2071343804
- Cited by
- 807
- References
- 32
- FWCI
- 32.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.